Our uniquely elegant mechanism of action combats antimicrobial resistance in numerous applications across multiple disease indications.


Our active pharmaceutical ingredient permeates biofilm, a protective environment for bacteria. Biofilm allows bacteria to thrive and become drug-resistant in a way that changes the physical nature of the biofilm, thus further protecting the bacteria.

Our asset inhibits metabolic activity within the bacterial cell, hindering its ability to survive, without lysing the cell and promoting antibacterial resistance.

This work made use of University of Utah USTAR shared facilities supported, in part, by the MRSEC Program of NSF under Award No. DMR-1121252.


Our studies have shown in vitro effectiveness against some of the world’s worst superbugs, including:

  • Gram negative bacteria

  • Gram positive bacteria

  • Non-tuberculosis mycobacteria

  • Fungus

  • multidrug-resistant Pseudomonas
  • Burkholderia
  • MSSA
  • MRSA
  • NTM’s
  • Achromobacter
  • Stenotrophomonas
  • Candida
  • Scedosporium


In May 2019 we received a prestigious grant from the Cystic Fibrosis Foundation to better understand the effect of our therapeutic on the microbes that pose the greatest threats to CF patients. Seattle Children’s Hospital conducted our in vitro studies.

The studies concluded that our API is a potent and non-toxic ingredient against the most problematic pathogens in the CF community. Given these preclinical results, EVQ-218 is a unique and promising therapy for cystic fibrosis beyond Pseudomonas.

In October 2021 we received an additional grant from CFF to continue our testing. This award will support the preclinical testing of our lead asset for the treatment of multi-drug resistant pulmonary bacterial infections in patients diagnosed with cystic fibrosis.